Disposition of [14C]-LY3502970 Following Oral Administration in Males
Research type
Research Study
Full title
Disposition of [14C]-LY3502970 Following Oral Administration in Healthy Male Participants
IRAS ID
285745
Contact name
Firas Almazedi
Contact email
Sponsor organisation
Eli Lilly and Company
Eudract number
2020-003160-60
Clinicaltrials.gov Identifier
20/NE/0233, REC Reference Number
Duration of Study in the UK
0 years, 2 months, 0 days
Research summary
The study drug (LY3502970) is an investigational drug which is being developed by the sponsor as a potential treatment for type 2 diabetes mellitus (T2DM).
With the prevalence of T2DM increasing world-wide, new treatments offering
significant improvements in blood sugar control which would result in improved health outcomes, are highly desired.Multiple treatments for T2DM exist however some of these treatments don’t achieve the desired results whilst others can have many side effects. It is hoped that the study drug will lead to better blood sugar control with fewer side effects in comparison to the currently available medications.
This study is being conducted at 1 research site only (our Unit). Up to 8 participants will be participating in this study.
Participants will receive a single dose of the study drug on 1 dosing occasion (once in the morning on Day 1). The planned dose level of study drug is 3 mg. The study drug will contain carbon-14 (a naturally occurring radioactive form of carbon) to allow the study drug and its breakdown products to be measured in the blood, urine, and feces. The reason for this is to allow different parts of the study drug to be traced after it has been broken down by the body.Participation in the study is expected to last up to 8 weeks from the time of screening to the last follow-up.
REC name
North East - York Research Ethics Committee
REC reference
20/NE/0233
Date of REC Opinion
18 Dec 2020
REC opinion
Further Information Favourable Opinion